Stage IV HER2-Positive Breast Cancer: Jennifer's Patient Story

Patient Info: Jennifer Feinberg, Female, 40s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: brain

8+ years after her initial breast cancer diagnosis, she was living with metastatic HER2-positive breast cancer with brain metastases and receiving trastuzumab as her tenth line of treatment.

Dana-FarberRead more →

Stage II Ovarian Cancer: Elizabeth's Survivor Story

Patient Info: Elizabeth Jardinella, Female, Under 40 | Stage II

Cancer-free for about 2 years, with surveillance scans continuing to show no evidence of disease while she takes maintenance letrozole.

MD AndersonRead more →

Stage IV Lung Cancer: Lorie's Patient Story

Patient Info: Lorie Young | Stage IV

Biomarkers: NTRK1 fusion

After a couple of months on TL-118, Lorie’s CT scan showed a strong response, while longer-term disease control remained uncertain.

MD AndersonRead more →

Stage IV HER2-Positive Breast Cancer: Tiffany's Patient Story

Patient Info: Tiffany Andrews, Female, Under 40 | Stage IV

Biomarkers: HER2-positive; ER-negative at recurrence

Metastatic Site: lungs|brain

Tiffany is living with metastatic HER2-positive breast cancer and continues treatment through a clinical trial after progression in the lungs and brain.

MD AndersonRead more →

Stage IV MSI-High Colorectal Cancer: Cindy's Patient Story

Patient Info: Cindy Mette, Female | Stage IV

Biomarkers: MSI-high

Cindy’s tumor responded to the experimental Werner helicase inhibitor, with falling CEA levels and radiologic response. The response was continuing in 2025 while she remained on the clinical trial.

MD AndersonRead more →

Stage IV Gastric Cancer: Derek's Patient Story

Patient Info: Derek Cooney | Stage IV

After a Stage IV stomach cancer diagnosis, an emergency physician sought several second opinions and enrolled in a clinical trial at UT MD Anderson.

MD AndersonRead more →

Stage IV EGFR Lung Cancer: Anne's Patient Story

Patient Info: Anne, Female | Stage IV

Biomarkers: EGFR-positive

Metastatic Site: spine; hips; lymph nodes; liver

Anne maintained a good quality of life for about 1 year on an oral EGFR-targeted medicine and later entered a clinical trial while continuing lung-cancer advocacy.

The Patient StoryRead more →

Stage IV MSI-High Colorectal Cancer: JJ's Patient Story

Patient Info: JJ, Male, Under 40 | Stage IV

Biomarkers: Lynch syndrome; microsatellite instability

Metastatic Site: Abdominal wall; lymph nodes throughout the body

At the latest scan, the main abdominal tumor remained stable. JJ had completed 126 rounds of chemo-immunotherapy and continued treatment every 3 weeks; small lung nodules were being watched but were not confirmed as metastases.

The Patient StoryRead more →

Stage II Triple-Negative Breast Cancer: Lucy's Survivor Story

Patient Info: Lucy, Female, Under 40 | Stage II

Biomarkers: Germline BRCA1 mutation; triple-negative breast cancer

Surgical pathology was all clear on June 17 after a strong chemotherapy response. Lucy described herself as cancer-free and continued oncology reviews every 3–4 months while planning delayed reconstruction.

The Patient StoryRead more →

Stage II Breast Cancer: Wendi's Survivor Story

Patient Info: Wendi Kushner | Stage II

Biomarkers: Triple-positive

After the clinical trial, lumpectomy pathology showed a complete pathological response with no residual cancer in the breast or lymph nodes.

MD AndersonRead more →

Stage IV Gastric Adenocarcinoma: Derek's Survivor Story

Patient Info: Derek Cooney, Male, 40s | Stage IV

Metastatic Site: peritoneum

At his first follow-up in June, scans showed no evidence of disease, and he later completed his pain-management fellowship.

MD AndersonRead more →

Stage III Colorectal Cancer: Haley's Survivor Story

Patient Info: Haley Pollack, Female, Under 40 | Stage III

Years into survivorship after Stage IIIC colon cancer treated with surgery, CAPOX chemotherapy, and a recurrence-prevention clinical trial; later continued trial follow-up and advocacy for parents with cancer.

The Patient StoryRead more →

Stage IV ALK Lung Cancer: Jake's Patient Story

Patient Info: Jake, Male, Under 40 | Stage IV

Biomarkers: ALK-positive mutation

Metastatic Site: brain; lung; ankle bone

As of May 2026, Jake was 28 and had lived more than 13 years with Stage IV ALK-positive lung cancer, with ongoing treatment history including targeted therapy, surgeries, radiation, clinical-trial therapy, and recent chemotherapy.

The Patient StoryRead more →

Stage III Colorectal Cancer: Jeffrey's Survivor Story

Patient Info: Jeffrey, Male | Stage III

As of May 2026, Jeffrey reported no evidence of disease, while remaining careful about surveillance language and managing lasting neuropathy after treatment.

The Patient StoryRead more →

Stage IV ALK Lung Cancer: Kartik's Patient Story

Patient Info: Kartik, Male, Under 40 | Stage IV

Biomarkers: EML4/ALK mutation

Kartik was diagnosed with Stage IV ALK-rearranged lung cancer at age 28, continued working for several years through a targeted clinical trial, and died in 2015 at age 34.

GO2 FoundationRead more →

Stage IV Colorectal Cancer: David's Patient Story

Patient Info: David, Male | Stage IV

Metastatic Site: Liver; lung; tailbone/bone

Had clear scans after multiple treatments for recurrent Stage IV colon cancer, but a later positive Signatera test suggested possible microscopic disease and more treatment was being planned.

The Patient StoryRead more →

Stage IV EGFR Lung Cancer: Kelsey's Patient Story

Patient Info: Kelsey, Female, Under 40 | Stage IV

Biomarkers: EGFR mutation; later ALK mutation after progression

Metastatic Site: Bone — pelvis and spine/L5

Living with Stage IV lung cancer on a clinical trial after progression, with current treatment described as working and quality of life improved.

The Patient StoryRead more →

Stage IV Colorectal Cancer: Joe's Patient Story

Patient Info: Joe, Male | Stage IV

Biomarkers: Specific biomarkers not reported

Metastatic Site: Liver; lymph nodes; lungs

Stage IV colon cancer initially reached no evidence of disease after FOLFOX plus panitumumab, but later recurred in the liver and lymph nodes, progressed to the lungs, and did not respond to later FOLFOX rechallenge or FOLFIRI before he started an immunotherapy clinical trial.

The Patient StoryRead more →

Stage IV Non-Small Cell Lung Cancer: Natalie's Patient Story

Patient Info: Natalie, Female, Under 40 | Stage IV

Metastatic Site: Spine

Natalie was living with Stage IV NSCLC after a double lung transplant gave her new lung function, but cancer later appeared in the spine and required renewed chemotherapy and radiation.

The Patient StoryRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Maggie's Patient Story

Patient Info: Maggie, Female, 60s | Stage IV

Biomarkers: EGFR mutation; MET amplification resistance mutation; MET overexpression

Metastatic Site: Brain

Maggie initially reached no evidence of disease on EGFR-targeted therapy, but later had repeated progression, including MET-amplification resistance and MET overexpression, requiring SBRT, a clinical trial, chemotherapy, and later-line targeted treatment.

The Patient StoryRead more →

Stage IV ROS1 Lung Cancer: Phil's Patient Story

Patient Info: Phil, Male, 60s | Stage IV

Biomarkers: ROS1 mutation

Metastatic Site: Lymph nodes; other lung

Phil was living with incurable Stage IV ROS1-positive lung cancer. After initial chemotherapy, a ROS1-targeted pill worked for about 2 years, and he later continued on a Mass General clinical-trial treatment with follow-up every 3 months.

The Patient StoryRead more →

Recovery from severe liver injury during Stage III gastric cancer treatment

Patient Info: Anonymized, Male, 70+ | Stage III

At the last follow-up in August 2025, imaging showed no recurrence and his liver function remained normal.

PubMed CentralRead more →

Stage IV Colorectal Cancer: Cora's Patient Story

Patient Info: Cora, Female | Stage IV

Metastatic Site: Liver; lungs

As of February 2026, Cora had recurrent Stage IV colorectal cancer with a positive ctDNA test but clear CT imaging after stopping an immunotherapy trial because of toxicity, so ongoing care and monitoring were still needed.

The Patient StoryRead more →

Stage II Triple-Negative Breast Cancer: Chase's Survivor Story

Patient Info: Chase, Female, Under 40 | Stage II

Biomarkers: ER-negative; PR-negative; HER2-negative

As of January 2026, Chase had shown no evidence of cancer for nearly 5 years after Stage IIB triple-negative breast cancer treatment and had completed 3 investigational vaccine injections without significant side effects.

Cleveland ClinicRead more →